LungLife AI

LungLife AI is a biotechnology startup based in the United States, founded in 2006. The company is dedicated to transforming lung cancer diagnosis and management through AI-enabled analysis of biomarkers in blood. LungLife's diagnostic solutions aim to significantly impact the early detection of lung cancer by utilizing a combination of rare cell recovery and blood-based biomarkers that have been shown to be altered in lung cancer. The core technology of LungLife is integrated into the LungLB® test, designed to provide physicians with additional information for decision-making regarding indeterminate lung nodules that may be lung cancer, with the potential to aid in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. Notably, over 1.5 million individuals with indeterminate lung nodules are diagnosed each year in the United States, presenting a significant market opportunity for LungLife's innovative diagnostic solution. In March 2024, LungLife AI secured a $315.78K post-IPO equity investment, signaling confidence and potential growth in the company's endeavors. With a successful 149 subject pilot study demonstrating a well-balanced performance and a Positive Predictive Value of 89%, LungLife is now poised to conduct a larger, multi-center validation study to gain regulatory and reimbursement support, paving the way for commercialization. This indicates a positive trajectory for the company as it advances in its mission to revolutionize lung cancer diagnosis and management.